Know Cancer

or
forgot password

Evaluation of Diagnostic Efficacy of Perfusion CT Using Wide Detector for Staging and Response Prediction After Chemotherapy in Pancreatic Cancer


N/A
18 Years
N/A
Not Enrolling
Both
Adenocarcinoma, Pancreas, Neuroendocrine Tumor, Pancreas

Thank you

Trial Information

Evaluation of Diagnostic Efficacy of Perfusion CT Using Wide Detector for Staging and Response Prediction After Chemotherapy in Pancreatic Cancer


1. Performance of preoperative perfusion CT for preoperative staging is assessed by
comparing with operative finding and histologic disease staging

2. Estimation of initial or change of pancreas cancer perfusion parameters and whether
those can provide cut-off value for predicting response of chemotherapy in patients
with pancreas adenocarcinoma


Inclusion Criteria:



- patients who are older than eighteen years

- patients in whom operation and preoperative computed tomography are scheduled for
resectable pancreas adenocarcinoma or pancreas neuroendocrine tumor

- patients in whom chemotherapy is scheduled for histologically confirmed pancreas
adenocarcinoma

- patients in whom chemotherapy is planned for highly suspicious pancreas
adenocarcinoma on imaging workup

- patients who agree with the study and whose informed consent is obtained.

Exclusion Criteria:

- patients who are younger than eighteen years old

- patients in whom previously radiation therapy was performed and the RTx field
includes pancreas

- patients with recurred pancreas adenocarcinoma

- patient who are pregnant or nursing patients

- patients with renal failure (GFR<30mL/min)

- patients with history of malignancy, except malignancy is in complete remission after
operation or iodine therapy for at least five years)

- patients with hypersensitivity for iodine or contrast media or other causes of
contraindication of contrast-media enhanced CT scan

- Any other condition which, in the opinion of the Investigator, would make the patient
unsuitable for enrollment or could interfere with the completion of the study.

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Principal Investigator

Jeong Min Lee, MD, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Seoul National University Hospital

Authority:

Korea: Institutional Review Board

Study ID:

SNUH_ISS_2012

NCT ID:

NCT01703650

Start Date:

November 2012

Completion Date:

February 2014

Related Keywords:

  • Adenocarcinoma, Pancreas
  • Neuroendocrine Tumor, Pancreas
  • CT
  • pancreas adenocarcinoma
  • RECIST
  • Adenocarcinoma
  • Adenocarcinoma, Mucinous
  • Pancreatic Neoplasms
  • Neuroendocrine Tumors

Name

Location